Entrada Therapeutics (TRDA) Accumulated Depreciation (2020 - 2021)
Entrada Therapeutics (TRDA) posted quarterly Accumulated Depreciation of $1.4 million for Q4 2021, up 275.6% year-over-year from $377000.0 in Q4 2020, and up 34.6% quarter-over-quarter from $1.1 million in Q3 2021.
Entrada Therapeutics (TRDA) Accumulated Depreciation (2020 - 2021) Analysis & Trends
Entrada Therapeutics' Accumulated Depreciation history runs 2 years deep, the most recent figure standing at $1.4 million for Q4 2021.
- In Q4 2021, Accumulated Depreciation rose 275.6% year-over-year to $1.4 million; the TTM figure through Dec 2021 stood at $1.4 million (up 275.6% YoY), while the FY2021 annual figure was $1.4 million, up 275.6% from the prior year.
- Accumulated Depreciation for Q4 2021 stood at $1.4 million, up from $1.1 million in the prior quarter.
- The five-year high for Accumulated Depreciation was $1.4 million in Q4 2021, with the low at $377000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.42 Mn |
| Sep 30, 2021 | 1.05 Mn |
| Dec 31, 2020 | 377,000.00 |